16-Jan-2026
No headlines found.
Stevanato Group Reports Revenue of EUR 303.2 Million for the Third Quarter of 2025
Business Wire (Thu, 6-Nov 6:30 AM ET)
Stevanato Group to Participate in Upcoming Investor Conferences
Business Wire (Fri, 31-Oct 7:30 AM ET)
Stevanato Group to Report Third Quarter 2025 Financial Results on November 6, 2025
Business Wire (Wed, 22-Oct 6:30 AM ET)
Stevanato Group Expands Drug Delivery Systems Capacity to Strengthen Global Integrated Offerings
Business Wire (Tue, 21-Oct 6:30 AM ET)
Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, the company derives majority revenue from Europe, Middle East and Africa.
Stevanato Group S.P.A. trades on the NYSE stock market under the symbol STVN.
As of January 16, 2026, STVN stock price declined to $19.75 with 403,495 million shares trading.
STVN has a beta of 0.78, meaning it tends to be less sensitive to market movements. STVN has a correlation of 0.09 to the broad based SPY ETF.
STVN has a market cap of $5.39 billion. This is considered a Mid Cap stock.
Last quarter Stevanato Group S.P.A. reported $355 million in Revenue and $.16 earnings per share. This beat revenue expectation by $19 million and exceeded earnings estimates by $.02.
In the last 3 years, STVN traded as high as $36.30 and as low as $16.56.
The top ETF exchange traded funds that STVN belongs to (by Net Assets): IBB, NBSM, KOMP, BCSM.
STVN has underperformed the market in the last year with a price return of -13.5% while the SPY ETF gained +18.1%. STVN has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -18.0% and -4.0%, respectively, while the SPY returned +5.0% and +1.2%, respectively.
STVN support price is $20.50 and resistance is $21.50 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that STVN shares will trade within this expected range on the day.